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Background: Universal and high-risk screening for gestational diabetes mellitus (GDM) has been widely studied
and debated. Few studies have assessed GDM screening in Asian populations and even fewer have compared Asian
ethnic groups in a single multi-ethnic population.
Methods: 1136 pregnant women (56.7% Chinese, 25.5% Malay and 17.8% Indian) from the Growing Up in
Singapore Towards healthy Outcomes (GUSTO) birth cohort study were screened for GDM by 75-g oral glucose
tolerance test (OGTT) at 26–28 weeks of gestation. GDM was defined using the World Health Organization
(WHO) criteria. High-risk screening is based on the guidelines of the UK National Institute for Health and Clinical
Excellence.
Results: Universal screening detected significantly more cases than high-risk screening [crude OR 2.2 (95% CI 1.7-2.8)],
particularly for Chinese women [crude OR = 3.5 (95% CI 2.5-5.0)]. Pre-pregnancy BMI > 30 kg/m2 (adjusted OR = 3.4, 95%
CI 1.5-7.9) and previous GDM history (adjusted OR = 6.6, 95% CI 1.2-37.3) were associated with increased risk of GDM in
Malay women while GDM history was the only significant risk factor for GDM in Chinese women (adjusted OR = 4.7,
95% CI 2.0-11.0).
Conclusion: Risk factors used in high-risk screening do not sufficiently predict GDM risk and failed to detect half the
GDM cases in Asian women. Asian women, particularly Chinese, should be screened to avoid under-diagnosis of GDM
and thereby optimize maternal and fetal outcomes.
Keywords: Universal screening, High risk screening, Gestational diabetes, Asians, EthnicBackground
Gestational diabetes mellitus (GDM), even when mild, can
have adverse consequences on the health of both mother
and child during pregnancy and early postpartum period
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unless otherwise stated.recurrence in subsequent pregnancies [3-5], and of
overt type 2 diabetes mellitus [4,6], while infants born
to mothers with GDM are at increased risk of develop-
ing obesity and diabetes in later life [7]. Studies have
shown that screening, detection and management of
GDM can mitigate the risk of adverse outcomes and
metabolic diseases in both mother and child [8-10]. The
development of GDM may thus be an indicator of
subsequent metabolic risk that requires identification
and appropriate management.
Factors such as family history of diabetes mellitus, ma-
ternal obesity, age >30 years and GDM in previous preg-
nancies have been reported to increase the risk of GDMLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oral glucose tolerance test (OGTT) is generally recognized
as the ‘gold standard’ for diagnosis of GDM [12].
It is controversial whether screening for GDM with
an OGTT in pregnant women should be universal
(testing all pregnancies) or selective (testing only pregnant
women with risk factors for GDM) [13,14]. American
Diabetes Association, American College of Obstetricians
and Gynecologists, UK National Institute for Health
and Clinical Excellence (NICE) recommend screening
in women with known risk factors [15-17] while other
organizations like International Association of Diabetes
and Pregnancy Study Groups (IADPSG) support universal
screening at 26–28 weeks gestation [18]. Results from sev-
eral studies indicate that universal screening for GDM in
certain populations is more sensitive and cost-effective
[14,19,20], especially in terms of preventing future type
2 diabetes.
Asians are at greater risk of GDM compared to their
Caucasian counterparts [21,22]. In Singapore, the three
major ethnic groups are all Asian: Chinese, Malay and
Indian. These three ethnicities jointly comprise over 40%
the global population [23]. To the best of our knowledge,
our study is the first to include these three ethnic groups
in a single cohort and to compare the proportion of GDM
using universal versus selective (high-risk for GDM) screen-
ing among them.
Methods
Pregnant women 18 years and above, who were in their
first trimester were recruited from the KK Women’s and
Children’s Hospital (KKH) and National University
Hospital (NUH) in Singapore between June 2009 and
September 2010 to participate in the Growing Up in
Singapore Towards healthy Outcomes (GUSTO) birth
cohort study. Our study included singletons and mul-
tiple pregnancies but only for the pregnancy when they
were recruited. These women were either Singapore
citizens or permanent residents from three different
ethnic groups with homogenous parental ethnic background
(both parents of the same ethnic group): Chinese, Malay,
and Indian. Women who were on chemotherapy, psycho-
tropic drugs or those with type 1 diabetes were excluded
[24]. Demographic data, family and obstetric history of
the subjects were obtained from interviewer-administered
questionnaires at the time of enrolment. Maternal pre-
pregnancy weight was self-reported. The study received
approval from Institutional Review Board (IRB) that re-
views ongoing research in KKH and NUH (Centralized
Institutional Review Board and Domain Specific Review
Board respectively). Informed written consent was obtained
from each participant.
Testing for GDM was performed using a 75-g oral
glucose tolerance test after overnight fasting (8 to 10 hours)at 26–28 weeks gestation. The 1999 World Health
Organization (WHO) standard criteria were selected
for the study define GDM: ≥7.0 mmol/L for fasting
glucose and/or ≥7.8 mmol/L for 2-hour post-glucose
[25,26] as blood glucose levels were only collected
twice (fasting and 2-hour post-glucose) for our study,
to minimize subject burden. Women with GDM were
subsequently managed according to standard protocols
practiced across both hospitals.
Participants were stratified according to risk factors for
GDM to compare the performance of a high-risk screening
approach to universal screening for detecting GDM.
Subjects were categorized as high-risk for GDM based
on the guidelines recommended by UK NICE if they fell
into one or more of the following categories: (1) obese
[body mass index (BMI) of >30.0 kg/m2], (2) family history
of type 2 diabetes (first-degree relative), (3) GDM in a pre-
vious pregnancy, (4) previous delivery of a baby with a birth
weight of ≥4.5 kg or (5) ethnic origin with known high
prevalence of diabetes (South Asians, black Caribbean,
Middle Eastern) [17]. As South Asian includes anyone
of family origin from India, Pakistan or Bangladesh, all
Indian subjects were classified as high-risk.
The McNemar chi-square test was performed to compare
the prevalence of detected GDM based on universal versus
high-risk screening using. Ordinary chi-square test was
utilized to compare the prevalence of detected GDM
across the ethnic groups. Logistic regression was used
to calculate the odds of GDM associated with each of
the risk factors used in high-risk screening. The odds ratios
for comparison across ethnic groups, were further ad-
justed for pre-pregnancy BMI > 30 kg/m2, family history
of diabetes, previous history of GDM and macrosomia.
Kruskal Wallis and Mann–Whitney U tests were applied
to examine differences in quantitative variables, and chi-
square test for categorical variables. There are missing data
on covariates [pre-pregnancy BMI (8.9%), family history of
diabetes (2.7%), previous history of births ≥4.5 kg (3.2%)
and GDM (3.1%)]. Multiple imputations of these variables
using Chained Equations imputation (20 imputations)
yielded very similar findings (data available upon request).
As such, missing data on covariates were excluded from the
analysis. All analyses were carried out using SPSS version
20.0 (IBM, Armonk, NY, USA).
Results
From June 2009 to September 2010, 1247 women were
enrolled in GUSTO birth cohort. Of these, 1136 (91.1%) re-
ceived the OGTT at 26–28 weeks gestation; the remaining
111 subjects either declined OGTT or missed their 26–28
weeks clinic visit. No significant differences were found
between the 1136 women who had OGTTs and the 111
women who did not have OGTT in terms of ethnicity
(with OGTT- 56.7% Chinese, 25.5% Malay and 17.8%
Table 2 Proportion of detected gestational diabetes
mellitus (GDM) in GUSTO cohort using universal versus
high-risk screeninga
Screening
methods
Whole cohort Chinese Malay Indian
(n = 1136) (n = 644) (n = 290) (n = 202)
Universalb 215 (18.9) 135 (21.0) 35 (12.1) 45 (22.3)
High-riskb 111 (9.8)c 45 (7.0)c 21 (7.2)c 45 (22.3)
aValues are given as number (%).
bUniversal screening is where all participants undergo oral glucose tolerance
test (OGTT); High-risk screening is where only participants with one or more of
the risk factors based on the guidelines from UK National Institute for Health
and Clinical Excellence (NICE) have to undergo OGTT.
cP < 0.001 compared to Universal Screening.
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Indian), age (mean ± SD, 30.7 ± 5.1 vs 30.6 ± 5.8 years),
parity (46.0% vs 40.2% primiparous), pre-pregnancy BMI
(22.7 ± 4.4 vs 22.8 ± 4.6 kg/m2), previous history of GDM
(3.4% vs 5.6%), family history of diabetes (29.4% vs 23.9%)
as well as previous births ≥4.5 kg (0.3% for both). The
demographic and clinical characteristics of all 1136 partic-
ipants who completed the 75-g OGTT are summarized in
Table 1. The predominant ethnic group was Chinese
(56.7%), followed by Malay (25.5%) and Indian (17.8%). We
oversampled Malay and Indian participants in order to have
ample statistical power to study the effect of ethnicity. The
Chinese women in this study were older and less obese
compared to the Malay and Indian women. They were also
more likely to be primiparous and less likely to have family
history of diabetes.
When the NICE guidelines for high-risk screening
were applied to GUSTO, 496 of the 1136 participants
who underwent OGTT, were classified as high-risk.
Universal screening detected a higher proportion of GDM
(18.9%, n = 215) than high-risk screening (9.8%, n = 111)
(Table 2). In other words, if OGTT had been performed
only in women considered high-risk by the NICE guide-
lines, almost half of the women with GDM would have
been missed.
As shown in Table 2, universal screening resulted in
GDM prevalence of 21.0%, 12.1% and 22.3% in Chinese,
Malay and Indian women respectively. GDM risk based on
universal screening remained higher in Chinese (adjusted
OR= 2.2, 95% CI 1.4-3.4) and Indian (adjusted OR= 2.2,
95% CI 1.3 -3.6) women relative to Malay women, afterTable 1 Maternal demographic and clinical characteristics of p
Chinese (n = 644)
Maternal age, y 31.7 ± 4.9
Primiparous 308 (47.8%)
Pre-pregnancy BMI, kg/m2 21.6 ± 3.4
BMI > 30 kg/m2 17 (2.6%)
BMI 25–30 kg/m2 68 (10.6%)
BMI <25 kg/m2 501 (77.8%)
Missing data 58 (9.0%)
Family history of diabetes mellitus 156 (24.8%)
Previous history of GDM 24 (3.8%)
Previous birth ≥4.5 kg 3 (0.5%)
One or more NICE risk factors except ethnicity 177 (27.5%)
Fasting plasma glucose ≥7.0 mmol/L 1 (0.2%)
2 h post OGTT Plasma glucose ≥7.8 mmol/L 135 (21.0%)
Abbreviations: BMI, Body Mass Index; GDM, gestational diabetes mellitus; NICE, UK N
tolerance test.
aValues are given as n (%) or mean ± SD.
*Analysed by Kruskal-Wallis test and chi-square test for qualitative variables categoradjusting for non-ethnicity related risk factors (Additional
file 1: Table S1). Overall sensitivity and specificity of
high-risk screening were 51.6% and 52.2% respectively
(Additional file 1: Table S2). Sensitivity of high-risk
screening is 33.3% in Chinese and 60.0% in Malay; specifi-
city is 74.1% and 62.4% respectively in Chinese and Malay
women. Indian women were all classified high-risk by NICE
guidelines because of their South Asian origin.
Pre-pregnancy BMI > 30 kg/m2 (OR= 3.3, 95% CI 1.5- 7.6)
and previous GDM history (OR= 7.6, 95% CI 1.5- 39.2) were
associated with increased risk of GDM in Malay women,
even after adjusting for all other risk factors (Table 3).
In Chinese women, only previous history of GDM was
associated with increased GDM risk (adjusted OR= 4.7, 95%
CI 2.0-11.0) while none of the non-ethnic risk factors was
significantly associated with GDM risk in Indians. Indian
ethnic origin was associated with a non-significant increase
in GDM risk [adjusted OR= 1.25 (95%CI 0.84-1.86)]. If thearticipants completing the 75-g oral glucose tolerance testa
Total (n = 1136)
P value*
Malay (n = 290) Indian (n = 202)
29.0 ± 5.5 29.7 ± 4.6 <0.001
116 (40.0%) 73 (36.1%) 0.005
24.4 ± 5.6 23.9 ± 4.4 <0.001
41 (14.1%) 18 (8.9%) <0.001
64 (22.0%) 49 (24.3%)
158 (54.5%) 119 (58.9%)
27 (9.3%) 16 (7.9%)
87 (31.0%) 91 (46.7%) <0.001
6 (2.1%) 9 (4.6%) 0.288
1 (0.4%) 0 (0%) 0.626
117 (40.3%) 101 (50.0%) <0.001
3 (1.0%) 1 (0.5%) 0.170
34 (11.7%) 45 (22.3%) 0.001
ational Institute for Health and Clinical Excellence; OGTT, oral glucose
ical variables, respectively.
Table 3 Ratios for associations between gestational diabetes mellitus and risk factors among the three ethnic groups
Risk factor Unadjusted odds ratio (95% CI) Adjusted odds ratios (95% CI)a
Chinese Malay Indian Chinese Malay Indian
Pre-pregnancy BMI >30 kg/m2 2.7 (1.0-7.2) 3.3 (1.5-7.6)b 1.8 (0.6-5.0) 2.4 (0.8-6.8) 3.4 (1.5-7.9)b 1.8 (0.6-5.1)
Family history of diabetes 1.0 (0.6-1.5) 1.6 (0.8-3.3) 1.2 (0.6-2.3) 0.8 (0.5-1.3) 1.6 (0.7-3.5) 1.2 (0.6-2.5)
Previous history of GDM 4.8 (2.1-11.0)b 7.6 (1.5-39.2)b 3.0 (0.8-11.6) 4.7 (2.0-11.0)b 6.6 (1.2-37.3)b 2.8 (0.7-11.0)
Previous birth ≥4.5 kg 1.9 (0.2-20.9) Not calculable* Not calculable* 3.9 (0.2- 62.9) Not calculable* Not calculable*
Abbreviations: BMI, Body Mass Index; GDM, gestational diabetes mellitus.
aAdjusted for other risk factors including pre-pregnancy BMI >30 kg/m2, family history of diabetes, previous history of GDM or birth weight ≥4.5 kg.
bP < 0.05 *Insufficient number of previous birth ≥ 4.5 kg to calculate.
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to include the overweight women, it is found to be as-
sociated with increased risk of GDM in both Chinese
(adjusted OR = 2.0, 95%CI 1.2- 3.3) and Malay (adjusted
OR= 3.3, 95% CI 1.5-7.1) women (data not shown in table).
In addition, maternal age (>25 years) was found to be
associated with increased GDM risk only in Malay
women (adjusted OR = 7.7, 95% CI 1.01-58.6) (data not
shown in table).
In this cohort, only 0.4% of the mothers were diagnosed
positive for GDM based on the fasting glucose WHO
cut-off, compared to 18.5% with the 2-hour post-glucose
cut-off. The low diagnosis rate with the fasting glucose was
consistent across all the ethnic groups (0.2%, 1.0% and 0.5%
in Chinese, Malay and Indian women respectively).
Discussion
Universal screening at 26–28 weeks gestation in a popula-
tion of Singaporean women of Chinese, Malay and Indian
ethnic origin, detected almost twice as many GDM cases
as a high-risk screening approach based on the NICE
guidelines. Individual risk factors used in high-risk screen-
ing showed poor sensitivity for GDM risk, particularly
among Indian women, in whom none of the risk factors
was associated with a significant increase in GDM risk.
Previous history of GDM significantly increased risk of
GDM in both Malay and Chinese women, but it is import-
ant to note that many of these women (47.8% and 40.0% in
Chinese and Malay women respectively) were primiparous.
While other studies have also shown that risk factors are
not independent predictors of GDM [27,28] in Asian popu-
lations, they have not compared these predictors among
distinct Asian ethnic groups.
Using the WHO criteria, the majority of GDM cases
were detected by the 2 h post-glucose levels across
all three ethnic groups in this cohort. Fasting glucose
levels were relatively low (mean = 4.37 mmol/L,
standard deviation = 0.54) whereas 2 h post-glucose
levels (mean = 6.57 mmol/L, standard deviation =1.61)
were higher than those reported in other ethnicities
(South Asian, Middle Eastern, Pacific Islander and
Anglo-European) [29]. Monnier et al. [30] previously re-
ported that the mean glycemic control was predominantlycontributed by postprandial glucose level in patients
with mild diabetes compared to standard type 2 dia-
betes where the fasting plasma glucose contributed
more to the glycemic control. This may imply that the
GDM observed in our population was a milder form of
diabetes which was more effectively picked up with the
2 h post-glucose levels.
Many studies have reported a strong association between
maternal obesity and the development of GDM [31-34].
In our cohort, Malay women had a higher rate of obesity
than Indian or Chinese women. Yet universal testing
indicated that Malay women had a lower prevalence of
GDM compared to either of the other two ethnic
groups. The reasons for this finding are unclear but we
speculate that it may be related to the differential distri-
bution of adipose tissue in different ethnic groups [35]
and/or differences in insulin resistance and β-cell func-
tion [36,37]. In view of these substantial physiological
differences across the ethnic groups, high-risk screening
will not work well in detecting GDM in a multi-ethnic
Asian population like Singapore.
The main strength of our study is the inclusion of
three Asian ethnic groups in our cohort. These ethnic
groups reflect more than 40% of the global population
[23]. While many studies have compared universal and
high-risk screening for GDM, few have been conducted
in Asian populations and none has compared the three
ethnic groups included in our study. One limitation of
our study is the lack of 1 h post-OGTT plasma glucose
reading, hence we used the 1999 WHO diagnostic criteria
instead of the revised 2013 WHO diagnostic criteria
[38]. We also acknowledge that our cohort may not be
representative of the Singapore population, as the par-
ticipants were recruited from only two hospitals. How-
ever, those are the two largest maternity hospitals in
the country and included both private and subsidised
patients. Selection bias may therefore influence the
prevalence of GDM observed among study participants
but should not bias associations between GDM and
ethnicity or any other risk factors. Another limitation
is that pre-pregnancy BMI was self-reported as partici-
pants were already pregnant at enrolment. Finally, we
were unable to examine the possible consequences of
Chong et al. BMC Pregnancy and Childbirth 2014, 14:345 Page 5 of 7
http://www.biomedcentral.com/1471-2393/14/345missed GDM detection, because (for ethical reasons)
every GDM case was referred for treatment.
Our findings suggest that clinical risk factors used in
defining high-risk population are poorly sensitive for
predicting GDM risk in the ethnic groups studied, particu-
larly for Chinese women. More than half of the GDM cases
would have been missed if high-risk screening was used.
Universal testing appears more appropriate for detecting
GDM in Asian populations. Although Indian women are
known to be at greater risk of GDM, routine screening of
Indian women is still not widely practiced in Asia. With
increasing migration of Asians to countries like Australia,
United States, Canada and United Kingdom, our findings
have important implications for screening strategies in
those countries as well [39].
Beneficial effects have been reported on both maternal
and fetal outcomes with detection and treatment of even
mild GDM [40-45]. Crowther et al. [40] demonstrated
that mothers with GDM randomised into an active
intervention group gave birth to infants with lower rate
of serious perinatal complications compared to routine-
care group. Kwik et al. [43] reported observational asso-
ciations between untreated GDM and macrosomia,
shoulder dystocia and preeclampsia. In another obser-
vational study among women treated for mild GDM,
higher fasting glucose during initiation of diet therapy
was associated with increased neonatal fat mass and
elevated C-peptide [46]; during the last two weeks before
delivery, higher fasting glucose was associated with
macrosomia, large for gestational age, and elevated
C-peptide [46]. Reduction of adverse outcomes with
detection and treatment of even mild GDM can be
cost-effective and reduces economic burden on health
care [47]. The United States Preventive Services Task Force
recently published their recommendation of screening all
asymptomatic women for GDM after 24 weeks of gestation,
in view of the moderate net benefit of GDM screening in
reducing maternal and fetal complications [48].
GDM has adverse long-term consequences for both
mother and offspring. Women with GDM have increased
risk of developing GDM in a subsequent pregnancy [3-5]
and type 2 diabetes within 5–10 years [4]. In addition,
children born from pregnancies affected by glucose in-
tolerance have higher risks for obesity and type 2 diabetes
in early adult life [3,4,7,49]. Detection of GDM is import-
ant to help identify high-risk women and their offspring
prior to the clinical onset of adverse consequences; appro-
priate interventions could reduce their future risk of type
2 diabetes and cardiovascular disease [50].
Conclusions
Our study suggests that universal screening for GDM
should be instituted in the Singapore population, particu-
larly for Chinese and Indian women. In the population westudied, selective screening failed to detect nearly half the
women with GDM. Timely detection of even mild GDM
is important to prevent adverse outcomes for both mother
and offspring. The current practice of high-risk screening
for GDM in most Asian countries will miss many cases
and thereby hinder prevention of its short- and long-term
adverse sequelae.
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